NeoGenomics (NG9) Stock Price & Analysis
NG9 Stock Chart & Stats
- Day’s Range
- EUR 15.83 - EUR 15.83
- 52-Week Range
- EUR 6.20 - EUR 17.26
- Previous Close
- EUR 15.93
- Volume
- N/A
- Average Volume (3M)
- 15
- Market Cap
- EUR 2.01B
- Enterprise Value
- EUR 2.67B
- Total Cash (Recent Filing)
- EUR 139.28M
- Total Debt (Recent Filing)
- EUR 449.14M
- Price to Earnings (P/E)
- ―
- Beta
- 0.84
- Next Earnings
- Feb 23, 2027 (Est.)
- EPS Estimate
- 0.06
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
NGS-led Growth
Rapid NGS growth is supported by new products, larger-panel adoption, higher-value mix, and demand across hematology and solid tumors. This broadens NeoGenomics’ role in oncology testing and provides a durable avenue for revenue and pricing growth.
Margin And EBITDA Expansion
Improving gross margin and EBITDA indicate operating leverage from favorable test mix, pricing, and laboratory efficiencies. If sustained, these gains can narrow losses, strengthen reinvestment capacity, and improve the economics of NeoGenomics’ expanding diagnostic platform.
Reimbursement And Market Access
Expanded reimbursement improves access to NeoGenomics’ MRD testing and can support adoption beyond self-pay or limited-coverage use cases. Additional indications under review could further enlarge the addressable market and reinforce the company’s oncology testing position.
Bears Say
Unprofitable Cash Profile
NeoGenomics has not yet converted improving operating performance into consistent profitability or self-funding cash flow. Continued cash burn can constrain investment flexibility and raises execution risk if margin expansion slows or growth initiatives require more capital.
Declining Nonclinical And Legacy Pharma Revenue
Declines in nonclinical and legacy pharma activities create a structural offset to growth in clinical diagnostics and NGS. Exiting low-margin contracts may improve quality over time, but the transition can weigh on reported revenue and complicate near-term growth execution.
Reimbursement And Policy Pressure
Unreimbursed MRD testing currently creates a gross-margin headwind before broader coverage is secured. Potential PAMA-related pressure could also reduce gross margin and EBITDA, requiring expense or investment trade-offs while reimbursement expansion remains incomplete.
NeoGenomics News
NG9 FAQ
What was NeoGenomics’s price range in the past 12 months?
What is NeoGenomics’s market cap?
When is NeoGenomics’s upcoming earnings report date?
How were NeoGenomics’s earnings last quarter?
Is NeoGenomics overvalued?
Does NeoGenomics pay dividends?
What is NeoGenomics’s EPS estimate?
How many shares outstanding does NeoGenomics have?
What happened to NeoGenomics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of NeoGenomics?
What is the TipRanks Smart Score and how is it calculated?
NeoGenomics Stock Smart Score
Company Description
NeoGenomics
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Anthony Zook
- Employees
- 2,500
- Website
- www.neogenomics.com
- Address
- 9490 NeoGenomics Way, Fort Myers, FL, 33912, US
NeoGenomics (NG9) Earnings & Revenues
NG9 Company Deck
NG9 Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, marked by 11% total revenue growth, 29% NGS growth, more than 300 basis points of adjusted gross-margin expansion, 53% adjusted EBITDA growth, and higher 2026 revenue and EBITDA guidance. Management also highlighted expanding MRD reimbursement, payer wins, product upgrades, sales-force investment, and a leadership transition occurring from a position of strength. The principal challenges were declining nonclinical revenue, legacy pharma pressure, near-term unreimbursed MRD testing, temporary receivables and cash-flow effects, and potential PAMA-related EBITDA pressure, but these issues were presented as manageable relative to the company's growth momentum.
View all DE:NG9 earnings summariesNG9 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 2 | 5 |
| Technical Analysis | 3 | 2 | 5 |
| Moving Averages | 12 | 0 | 0 |
